Businessman Races Against Inherited Alzheimer's Gene
Translated & summarized from Ice by baba
Businessman Ofer Shina, 38, is racing against time after discovering he carries a gene mutation linked to early-onset Alzheimer's, which claimed his father's life. He is now leading a US biotech company, ExtoZis, developing a treatment based on Israeli research, which received a $2.74 million grant from the Michael J. Fox Foundation. Shina hopes for human trials within 18 months, though full approval may take six years.
The story in 5 lines · by baba
- Ofer Shina, 38, is battling a hereditary gene mutation linked to early-onset Alzheimer's.
- The mutation previously caused the death of his father and affects other family members.
- Shina is leading a US biotech company, ExtoZis, developing a treatment based on Israeli research.
- ExtoZis received a $2.74 million grant from the Michael J. Fox Foundation.
- Human trials are hoped for within 18 months, but full approval could take six years.
Ofer Shina, a 38-year-old businessman and son-in-law of journalist Shlomi Eldar, is engaged in a personal race against time as he battles a genetic mutation that caused his father's death and now threatens his own life. Shina discovered he carries a hereditary mutation in the PSEN1 gene, linked to early-onset Alzheimer's disease. This discovery has spurred him to lead a US-based biotechnology company, ExtoZis, which is developing a treatment based on Israeli research. The company recently received a $2.74 million grant from the Michael J. Fox Foundation to advance a treatment candidate towards human trials, initially for Parkinson's disease.
In an interview with Oded Ben Ami on Channel 12, Shina revealed that the disease has affected many family members, sometimes appearing in their 40s. His father passed away when Shina was just six years old. He confirmed he is a carrier of the gene and noted that his son was tested during family planning and found to be clear of the gene. His father-in-law, Shlomi Eldar, shared the interview online, expressing pride and concern for his son-in-law's fight.
Shina, who has 13 years of experience in high-tech product management but no formal biology training, immersed himself in scientific literature. After reviewing over 200 approaches and thousands of articles, he encountered the research of Professor Varda Shoshan-Ramatz from Ben-Gurion University. Initially, Professor Shoshan-Ramatz was skeptical of Shina's approach, as he lacked investors or funding. Dr. Galit Mazuz Perlmuter of BG-Tech also delayed engagement for a year, but Shina persisted.
ExtoZis was established to advance the treatment based on the Israeli research. While the Michael J. Fox Foundation grant is a significant step, the path to commercial approval is long. Erin Henderson, CEO of ExtoZis, estimates that even in an optimistic scenario, approval could take about six years, acknowledging the uncertainty of whether the treatment will be available in time for Shina. Shina chose to establish the company in the United States to expedite the regulatory process, hoping to reach human trials within 18 months for himself and other patients.
